GlassScriptPhysician profile
Joyti Gore
NPI 1225711120
$2,385.02
in general payments reported to CMS, 2019-2025
24 companies · $1,441 in 2025
The $1,441 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $39.51 · 2024: $905 · 2025: $1,441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,211 · Education: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,211.02 |
| Education | $174.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $298.08 | 2024-2025 | |
| Astellas Pharma US INC | $267.29 | 2024-2025 | Vyloy, Xospata |
| Merck Sharp & Dohme LLC | $210.91 | 2024-2025 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $193.12 | 2023-2025 | |
| Array Biopharma INC | $184.58 | 2024-2025 | Mektovi, Tukysa, Braftovi |
| Janssen Biotech, INC. | $165.89 | 2024-2025 | Rybrevant, Talvey, Darzalex |
| Lilly USA, LLC | $109.12 | 2024 | Verzenio, Jaypirca |
| Bayer Healthcare Pharmaceuticals INC. | $106.36 | 2024-2025 | |
| Agios Pharmaceuticals, INC. | $90.78 | 2024-2025 | Pyrukynd |
| Emd Serono, INC. | $89.31 | 2024-2025 | |
| Legend Biotech USA INC. | $88.52 | 2024-2025 | Carvykti |
| Karyopharm Therapeutics INC. | $80.60 | 2024-2025 | Xpovio |
| Pharmaessentia USA Corporation | $65.23 | 2025 | Besremi |
| Novartis Pharmaceuticals Corporation | $64.74 | 2025 | |
| Abbvie INC. | $53.05 | 2024-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $49.62 | 2025 | Alunbrig, Fruzaqla |
| Blueprint Medicines Corporation | $49.04 | 2024 | Ayvakit |
| Astrazeneca Pharmaceuticals LP | $48.85 | 2025 | Enhertu |
| Aveo Pharmaceuticals, INC. | $42.37 | 2024-2025 | |
| Spectrum Pharmaceuticals INC. | $38.54 | 2025 | Rolvedon |
| Genentech USA, INC. | $26.56 | 2025 | Tecentriq Hybreza |
| Puma Biotechnology, INC. | $26.39 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $19.62 | 2024 | Libtayo |
| E.R. Squibb & Sons, L.L.C. | $16.45 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joyti Gore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.